Amandine Devaux and Romain Villger were supported by a FRM grant and by a CPER EPICURE 2016 grant respectively
Native rhIGF-1 (mecasermin, brand name Increlex) is FDA-approved only for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency or with GH gene deletion who have developed neutralizing antibodies to GH
Often, patients with this condition feel ashamed, which makes it difficult for them to seek treatment
Abstract Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejection fraction (HFpEF), it reduced weight, lowered blood pressure, and improved outcomes
tb , only a small portion of about 5-10% develop the disease in their lifetime ( The standard therapeutic regimen to treat active TB recommended by the Center for Disease Control and Prevention (CDC) is a multidrug regimen of antibiotics taken from 6 to 9 months known as DOTS (Directly Observed Treatment, Short-course) ( One approach to combat M
These patient testimonials prove our approach works and inspire others